Argenx Se ARGX
NASDAQ ARGX
$1,039.24 -14.21 (-1.35%)
As of: Sep 4, 2026 · 11:44 AM EDT

Argenx Se (ARGX) Long-Term Deferred Tax (2016 - 2026)

Argenx Se's (ARGX) quarterly Long-Term Deferred Tax came in at $1.4 billion in Q2 2026, down 99.84% YoY from $899.6 billion in Q2 2025, and up 10.26% on a QoQ basis from $1.3 billion in Q4 2025.

Analysis

Argenx Se (ARGX) Long-Term Deferred Tax (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has 11 years of Long-Term Deferred Tax data on file, last reported at $1.4 billion in Q2 2026.

  • Quarterly Long-Term Deferred Tax fell 99.84% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 99.84% YoY) and the FY2025 annual result came in at $1.3 billion, up 40.21% from the prior year.
  • Long-Term Deferred Tax improved to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $899.6 billion in Q2 2025 to a low of $54.3 million in Q2 2022.
  • A 5-year average of $100.4 billion and a median of $174.6 million in 2024 frame the typical range for Long-Term Deferred Tax.
  • Annual changes were most pronounced in 2025 — Long-Term Deferred Tax jumped 515062.12% — and 2026, when it plunged 99.84%.
  • Tracing ARGX's Long-Term Deferred Tax over 5 years: stood at $79.2 million in 2022, then rose by 22.71% to $97.2 million in 2023, then soared by 850.82% to $924.3 million in 2024, then jumped by 40.21% to $1.3 billion in 2025, then grew by 10.26% to $1.4 billion in 2026.
  • The last three Long-Term Deferred Tax figures came in at $1.4 billion (Q2 2026), $1.3 billion (Q4 2025), and $899.6 billion (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 140.22 Bn 132.37 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn
3 Argenx Se 63.70 Bn 58.52 Bn 1.37 Bn
4 Moderna 57.56 Bn 52.42 Bn 52.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn -
6 BeOne Medicines 40.16 Bn 35.06 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.63 Bn 32.32 Bn 992.69 Mn
8 Royalty Pharma 28.63 Bn 27.79 Bn -
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn
10 Incyte 25.60 Bn 21.07 Bn 1.57 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.43 Bn
Dec 31, 2025 1.30 Bn
Jun 30, 2025 899.61 Bn
Dec 31, 2024 924.30 Bn
Jun 30, 2024 174.63 Mn
Dec 31, 2023 97.21 Mn
Jun 30, 2023 138.77 Mn
Dec 31, 2022 79.22 Bn
Jun 30, 2022 54.27 Mn
Dec 31, 2021 32.19 Bn
Jun 30, 2021 16.25 Mn
Dec 31, 2020 14.61 Bn
Dec 31, 2019 44.28 Mn
Dec 31, 2018 33.44 Mn
Dec 31, 2017 33.44 Mn
Dec 31, 2016 22.67 Mn